Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 12, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 7,463 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on September 8, 2006, and was advised to the Company on September 11, 2006.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors—Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop—hold an interest in the shares held within the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual items beyond this standard disclosure are mentioned.
Investor Verification Points
- Verify the total number of shares transferred (7,463) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the date of the transaction (September 8, 2006) versus the date of notification to the Company (September 11, 2006).
- Review the status of the GSK Trust as a discretionary trust for employee beneficiaries.
- Note that this filing does not contain financial results; investors should refer to Form 20-F for financial data.